Contrasting Catalent (CTLT) and Its Rivals
Catalent (NYSE: CTLT) is one of 105 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Catalent to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, analyst recommendations, valuation and dividends.
Valuation and Earnings
This table compares Catalent and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Catalent||$2.08 billion||$109.80 million||46.05|
|Catalent Competitors||$8.17 billion||$1.09 billion||146.93|
Insider and Institutional Ownership
99.5% of Catalent shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of Catalent shares are owned by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Catalent and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and recommmendations for Catalent and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Catalent presently has a consensus target price of $44.00, suggesting a potential upside of 9.84%. As a group, “Pharmaceuticals” companies have a potential upside of 21.97%. Given Catalent’s peers higher probable upside, analysts clearly believe Catalent has less favorable growth aspects than its peers.
Volatility and Risk
Catalent has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Catalent’s peers have a beta of 34.18, indicating that their average share price is 3,318% more volatile than the S&P 500.
Catalent peers beat Catalent on 7 of the 13 factors compared.
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.